Author

Abby L Klauer

Observed names: Abby Klauer, Abby L. Klauer

Institution: JMI Laboratories

Observed institution: JMI Laboratories

ORCID: 0000-0002-9881-8286

Observed ORCID: 0000-0002-9881-8286

OpenAlex ID: A5012264366

Evaluation of Rezafungin Provisional CLSI Clinical Breakpoints and Epidemiological Cutoff Values Tested against a Worldwide Collection of Contemporaneous Invasive Fungal Isolates (2019 to 2020)

2022 · Cecilia G. Carvalhaes, Abby L. Klauer, et al. · Journal of Clinical Microbiology · 41

In vitro activity of manogepix and comparators against infrequently encountered yeast and mold isolates from the SENTRY Surveillance Program (2017–2022)

2024 · Michael Pfaller, Michael Huband, et al. · Antimicrobial Agents and Chemotherapy · 26

Anidulafungin is a useful surrogate marker for predicting in vitro susceptibility to rezafungin among five Candida species using CLSI methods and interpretive criteria

2025 · Marisa L. Winkler, Lalitagauri Deshpande, et al. · Journal of Clinical Microbiology · 4

1731. Rezafungin Activity against Candida spp. and Aspergillus spp. Isolates Causing Invasive Infections Worldwide in 2021

2022 · Cecilia G Carvalhaes, Paul Rhomberg, et al. · Open Forum Infectious Diseases · 3

2115. Rezafungin Activity against Invasive Candidiasis Isolates Globally: Results from the 2022 Rezafungin Surveillance Program

2023 · Cecilia G Carvalhaes, Paul Rhomberg, et al. · Open Forum Infectious Diseases · 2

1076. Activity of Rezafungin and Comparator Antifungal Agents Tested Against a Worldwide Collection of Contemporaneous Invasive Fungal Isolates (2019-2020)

2021 · Cecilia G Carvalhaes, Abby L Klauer, et al. · Open Forum Infectious Diseases · 2

1044. In vitro Activity of Tebipenem Against Relevant Clinical Isolates in the Presence of Pulmonary Surfactant

2021 · S J Ryan Arends, Abby L Klauer, et al. · Open Forum Infectious Diseases · 1

1041. In vitro activity of tebipenem against a recent collection of fastidious organisms recovered from respiratory tract infections

2021 · S J Ryan Arends, Abby L Klauer, et al. · Open Forum Infectious Diseases · 1

Activity of manogepix and comparator antifungal agents against uncommon filamentous fungal isolates collected in a global surveillance program

2026 · Marisa L. Winkler, Abby Klauer, et al. · Microbiology Spectrum

Activity of Isavuconazole and Comparator Agents Against Pediatric Isolates From Invasive Fungal Infections

2026 · Marisa L Winkler, Paul Rhomberg, et al. · Journal of the Pediatric Infectious Diseases Society

P-1195. Activity of manogepix against surveillance yeast isolates collected from the United States in 2023

2026 · Marisa Winkler, Samuel Edeker, et al. · Open Forum Infectious Diseases

P-1194. Activity of manogepix against mould isolates collected from the US in 2023

2026 · Marisa Winkler, Samuel Edeker, et al. · Open Forum Infectious Diseases

P-1193. Activity of isavuconazole against contemporary Mucorales from a worldwide surveillance program

2026 · Marisa Winkler, Samuel Edeker, et al. · Open Forum Infectious Diseases

P-1196. Geographic distribution, MIC testing, and susceptibility rates of Candida auris isolates collected in the United States since 2014

2026 · Marisa Winkler, John Kimbrough, et al. · Open Forum Infectious Diseases

1947. Activity of Rezafungin against Echinocandin–Non-wild type C. glabrata Clinical Isolates from the Rezafungin Surveillance Program (2014–2021)

2023 · Cecilia G Carvalhaes, Paul Rhomberg, et al. · Open Forum Infectious Diseases

2113. Evaluation of Isavuconazole Activity against Aspergillus fumigatus Causing Invasive Infections Worldwide Using the New CLSI Clinical Breakpoints

2023 · Cecilia G Carvalhaes, Paul Rhomberg, et al. · Open Forum Infectious Diseases

1038. In Vitro Activity of Tebipenem, an Orally Available Carbapenem Agent, Against a Collection of Surveillance Gram-Positive Clinical Isolates

2021 · S J Ryan Arends, Abby L Klauer, et al. · Open Forum Infectious Diseases

Works count: 17

Citation count: 80

H-index: 3

I10-index: 2